Liraglutide

Liraglutide was the first once-daily GLP-1 receptor agonist, representing a significant advance over twice-daily exenatide through its C16 fatty acid modification that enables albumin binding. With 97% sequence homology to native GLP-1, it produces physiologically relevant GLP-1 receptor activation.

The compound demonstrated that fatty acid acylation could dramatically extend peptide half-life while maintaining receptor activity, establishing a modification strategy subsequently applied to semaglutide and other peptide drugs. The palmitic acid moiety binds reversibly to albumin, creating a circulating reservoir that extends half-life to approximately 13 hours.

Research established liraglutide's effects on glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite reduction. Cardiovascular outcome trials demonstrated reduced major adverse cardiovascular events, expanding understanding of GLP-1 biology beyond glucose metabolism.

While newer agents like semaglutide have achieved longer half-lives and greater weight loss effects, liraglutide remains an important reference compound for GLP-1 research and established the foundation for incretin-based therapeutic development. Its extensive clinical database provides valuable long-term safety information for the GLP-1 agonist class.